LXRX Prakiraan wutah bathi kanggo taun ngarep lexpharma.com
Lexicon Pharmaceuticals (LXRX) maintains a high reputation in the therapy of heart failure and metabolic disorders. The growth trajectory of next year's EPS allows for an assessment of market expectations, where -32.80 represents the latest level. Development is based on compliance with laboratory eco-standards and the implementation of ESG principles through logistics optimization and the safe disposal of chemicals to minimize environmental impact.
LXRX (Lexicon Pharmaceuticals Inc): rincian analitis lan laporan miturut indikator
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi pasar:
- indikator kapitalisasi buku:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal Lexicon Pharmaceuticals|LXRX - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Lexicon Corp|LXRX - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Lexicon Pharma|LXRX - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Lexicon Pharmaceuticals|Rasio cepet lexpharma.com
- data bathi resik lan rasio valuasi:
LXRX - Penghasilan resik perusahaan|Bathi mangsa ngarep Lexicon Pharmaceuticals|LXRX - Pangali rega marang bathi|Pangali Forward P/E Lexicon Pharmaceuticals Inc|LXRX - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA Lexicon Pharma|LXRX - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Lexicon Pharmaceuticals|LXRX - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan lexpharma.com|LXRX - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Lexicon Pharmaceuticals
- data total pendapatan lan volume dodolan:
Analisis wiwitan perusahaan:LXRX, lexpharma.com
Institutional capital utilizes fundamental metrics to filter market noise from the actual value of a business. This indicator measures the average expected growth in earnings per share, reflecting the market consensus regarding future profitability. By analyzing the trend of consensus EPS forecasts for the coming year, an investor assesses the potential for profit scaling. For Lexicon Pharmaceuticals (LXRX), this growth depends directly on the effectiveness of commercializing innovative drugs for the therapy of cardiovascular pathologies.
Analisis perusahaan pesaing
ASND (Ascendis) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep Madrigal Pharmaceuticals|Prakiraan wutah bathi kanggo taun ngarep CORT|Prakiraan wutah bathi resik saben saham kanggo taun ngarep RYTM (Rhythm Pharma)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep akerotx.com AKRO|Metsera Therapeutics (MTSR) - Prakiraan wutah bathi resik saben saham ing taun ngarep|MLTX - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|CRNX: Prakiraan wutah bathi resik saben saham kanggo taun ngarep|NAMS: Prakiraan wutah bathi kanggo taun ngarep|SLNO - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Amicus Corp|89bio Pharma (ETNB) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep agios.com (AGIO)|Prakiraan wutah bathi saben saham kanggo taun ngarep structuretx.com GPCR|Prakiraan wutah bathi resik saben saham kanggo taun ngarep MiMedx Group Inc MDXG|Dinamika bathi saben saham sing diarepake ing taun ngarep RZLT|MBX: Prakiraan wutah bathi saben saham kanggo taun ngarep|Altimmune Corp - Proyeksi tambahing bathi saben saham ing taun ngarep|Aardvark Therapeutics Inc (AARD) - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi saben saham kanggo taun ngarep Biomea Fusion (BMEA)|Prakiraan wutah bathi kanggo taun ngarep QNCX|Proyeksi tambahing bathi saben saham ing taun ngarep GUTS|Prakiraan wutah bathi kanggo taun ngarep VTVT (vTv Therapeutics Inc.)|Dinamika bathi saben saham sing diarepake ing taun ngarep ATPC|Pluristem Therapeutics - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep synlogictx.com SYBX|LPCN: Prakiraan wutah bathi kanggo taun ngarep|Matinas BioPharma Holdings, Inc. - Dinamika bathi saben saham sing diarepake ing taun ngarep|SPRB (Spruce Biosciences Inc.) - Prakiraan wutah bathi kanggo taun ngarep|galecto.com (GLTO) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep organovo.com ONVO|Radius Health (RDUS) - Prakiraan wutah bathi resik saben saham ing taun ngarep
